Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?
Inmaculada Jarrín(Instituto de Salud Carlos III), Javier Martínez‐Picado(Universitat de Vic - Universitat Central de Catalunya), Dominique Costagliola(Inserm), Judith Dalmau, Kholoud Porter(The Royal Free Hospital), Faroudy Boufassa(Inserm), Cristina Mussini(University of Modena and Reggio Emilia), Julià Blanco(IrsiCaixa), Nikos Pantazis(National and Kapodistrian University of Athens), Andrew N. Phillips(University College London), Ashley Olson(MRC Human Nutrition Research)
Cited by 21
Related Papers
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
|International Journal of Obesity|2012|2.1k
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy
|AIDS|2014|597
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial
|Clinical Infectious Diseases|2018|424